Enlivex Therapeutics

Yahoo Finance • 8 days ago

Enlivex anuncia una colocación privada de $212,000,000 para iniciar la primera estrategia de tesorería de activos digitales basada en mercados de predicción en el mundo, mediante la acumulación del token RAIN, y el nombramiento de Matteo Renzi, ex Primer Ministro de Italia, como miembro de su directorio.

- Tras el cierre de la colocación privada, Enlivex adoptará la primera estrategia de tesorería de activos digitales basada en mercados de predicción del mundo, mediante la acumulación del token RAIN. - RAIN es un protocolo totalmente desc... Full story

Yahoo Finance • 8 days ago

Enlivex mengumumkan Penempatan Persendirian bernilai AS$212,000,000 untuk Memulakan Strategi Perbendaharaan Aset Digital Pasaran Ramalan Pertama di Dunia, melalui Pengumpulan token RAIN, serta Pelantikan Matteo Renzi, Bekas Perdana Menteri Itali, ke dalam Lembaga Pengarahnya

- Selepas penutupan penempatan persendirian, Enlivex akan mengguna pakai strategi perbendaharaan aset digital token pasaran ramalan RAIN pertama di dunia melalui pengumpulan token RAIN. - RAIN ialah protokol ramalan dan opsyen yang terdes... Full story

Yahoo Finance • 8 days ago

Enlivex Anuncia Colocação Privada de US $212.000.000 para Início da Primeira Estratégia de Previsão de Mercados de Tesouro de Ativos Digitais do Mundo, via Acumulação de tokens RAIN, e a Nomeação de Matteo Renzi, Ex-Primeiro-Ministro da Itália, para seu Conselho

- Após o fechamento da colocação privada, a Enlivex adotará a primeira estratégia de tesouro de ativos digitais de token de previsão RAIN do mundo, por meio do acúmulo de token RAIN. - RAIN é um protocolo de previsões e opções totalmente... Full story

Yahoo Finance • 8 days ago

エンライベックス (Enlivex)、RAINトークンの蓄積を通じた世界初の予測市場デジタル資産財務戦略を開始するための2億1,200万ドル (約333億円) の私募および、イタリア元首相マッテオ・レンツィ (Matteo Renzi) の取締役任命を発表

- 私募のクロージング後、エンライベックスはRAINトークンの蓄積を通じて、世界初のRAIN予測市場トークンデジタル資産財務戦略を採用する。 - RAINは完全に分散化された予測・オプションプロトコルで、予測市場エコシステムを再定義し、透明性、自動化、コミュニティ参加を基盤としたオンチェーン市場創出のための強力なプラットフォームを提供する。 - イタリア元首相マッテオ・レンツィ氏が、私募のクロージング後、エンライベックス取締役に任命される。 - エンライベックスは、変... Full story

Yahoo Finance • 9 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Inspire Veterinary Partners In 228,272,504 0.1902 0.1538 0.1581 +0.0369... Full story

Yahoo Finance • 9 days ago

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol... Full story

Yahoo Finance • 9 days ago

Enlivex stock gains on upbeat 6-month results in knee osteoarthritis trial

[Hygiene women worker work in science laboratory. people in pharmaceutical medicine production machine inspector.] coffeekai * Enlivex Therapeutics (ENLV [https://seekingalpha.com/symbol/ENLV]) on Monday reported [https://seekingalpha.c... Full story

Yahoo Finance • 9 days ago

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Ph... Full story

Yahoo Finance • last month

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster a... Full story

Yahoo Finance • 2 months ago

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Infl... Full story

Yahoo Finance • 4 months ago

What's going on in today's session

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNGX... Full story

Yahoo Finance • 4 months ago

Monday's session: top gainers and losers

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT SNGX [https://www.chartmill... Full story

Yahoo Finance • 4 months ago

Let's uncover which stocks are experiencing notable gaps during today's session.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. [gap] TOP GAP UP STOCKS TICKER CHANGE COM... Full story

Yahoo Finance • 4 months ago

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

ENX-CL-05-001 Trial: 3-months topline data -   In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee functi... Full story

Yahoo Finance • 4 months ago

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage o... Full story

Yahoo Finance • 2 years ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik... Full story

Yahoo Finance • 2 years ago

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled.The... Full story

Yahoo Finance • 3 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Nes-Ziona, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced that the U.S.... Full story

Yahoo Finance • 3 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategyFormer EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities a... Full story

Yahoo Finance • 3 years ago

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical collaboration with BeiGene. to evaluat... Full story